Objective To investigate the characteristics and outcome of abnormal vaginal bleeding in
women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE) …

Abnormal vaginal bleeding can complicate direct oral anticoagulant (DOAC) treatment. We
aimed to investigate the characteristics of abnormal vaginal bleeding in patients with venous …

Introduction Rivaroxaban is a convenient oral anticoagulant for patients with venous
thromboembolism (VTE). The impact of rivaroxaban and vitamin K antagonists (VKAs) on …

Abnormal uterine bleeding (AUB) is a common complication of anticoagulant therapy in
premenopausal women affected with acute venous thromboembolism. AUB impacts quality …

Background Observational data and results from post-hoc analyses in clinical trials suggest
that direct oral factor Xa inhibitors might increase menstrual bleeding intensity in women of …

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of
the potential for fetal complications. It is unknown whether the use of hormonal therapy …

Essentials• Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than
vitamin‐K antagonists (VKA).• We analyzed data of AUB in women, evaluating dabigatran …

Background Women presenting with uterine bleeding during the course of anticoagulant
therapy for venous thromboembolism (VTE) present a difficult therapeutic dilemma due to …

Preliminary data and clinical experience have suggested an increased risk of abnormal
uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid …

Estrogen exposure, in the setting of pregnancy, the postpartum state, combined hormonal
contraceptives (CHCs), or hormone therapy use, has been clearly associated with increased …